Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Hikma Pharmaceutical (HKMPF)

Hikma Pharmaceutical (HKMPF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,419,508
  • Shares Outstanding, K 240,867
  • Annual Sales, $ 2,070 M
  • Annual Income, $ 282,000 K
  • 60-Month Beta 0.22
  • Price/Sales 2.62
  • Price/Cash Flow 11.96
  • Price/Book 3.19
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 07/03/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.9000 +7.66%
on 06/14/19
22.5000 unch
on 07/10/19
-0.3500 (-1.53%)
since 05/16/19
3-Month
20.9000 +7.66%
on 06/14/19
22.9000 -1.75%
on 04/30/19
-0.9000 (-3.85%)
since 04/09/19
52-Week
14.0000 +60.71%
on 07/24/18
26.3964 -14.76%
on 11/08/18
+3.2500 (+16.88%)
since 07/10/18

Most Recent Stories

More News
Hikma and Civica Rx sign long-term agreement to reduce generic drug shortages in the US

Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable), the multinational generic pharmaceutical company and Civica Rx (Civica,...

HKMPF : 22.5000 (unch)
HKMPY : 42.4100 (+2.32%)
Hikma Sponsors MIT Grand Hack to Support Global Healthcare Innovation

Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the multinational generic pharmaceutical company, today announced that it will serve as a Gold Sponsor of the Massachusetts...

HKMPF : 22.5000 (unch)
HKMPY : 42.4100 (+2.32%)
Hikma launches 100th injectable medicine in US with introduction of Vancomycin Hydrochloride for Injection, USP

Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) the multinational pharmaceutical company, today launched its 100th injectable...

HKMPF : 22.5000 (unch)
HKMPY : 42.4100 (+2.32%)
Biolinq Expands Series A Financing With $4.75 Million Investment

Biolinq, a health technology company with a unique wirelessly-enabled biosensor patch capable of continuously monitoring multiple biomarkers, today announced it has expanded its oversubscribed...

HKMPF : 22.5000 (unch)
Hikma Pharmaceuticals Plc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2019 / Hikma Pharmaceuticals Plc (OTC PINK: ) will be discussing their earnings results in their 2018 Second Half Earnings to be held on March 12, 2019, 2018 at 9:30...

HKMPF : 22.5000 (unch)
Ironwood Commences Phase I Study on IW-6463 for CNS Disorders

Ironwood (IRWD) begins a phase I study on CNS-penetrant soluble guanylate cyclase stimulator, IW-6463, for treating severe CNS disorders.

IRWD : 10.92 (-0.36%)
AGN : 161.89 (-0.46%)
HKMPF : 22.5000 (unch)
IONS : 63.96 (-7.14%)
Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza

Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.

CPIX : 5.71 (+0.88%)
HKMPF : 22.5000 (unch)
BSTC : 61.03 (-1.85%)
OCUL : 4.43 (-1.12%)
Karyopharm Files MAA for Myeloma Candidate Selinexor in EU

Karyopharm (KPTI) tenders a marketing application to European regulatory authority with the purpose of seeking an approval for selinexor to address patients with penta-refractory multiple myeloma.

JNJ : 128.84 (+0.16%)
HKMPF : 22.5000 (unch)
KPTI : 8.81 (+5.76%)
BSTC : 61.03 (-1.85%)
Neurocrine Gives Ingrezza Sales View, Updates on Pipeline

Neurocrine (NBIX) issues preliminary sales outlook for Ingrezza with respect to the fourth quarter of 2018 as well as the full year. The company also lends an update on its pipeline.

NBIX : 85.71 (-1.29%)
HKMPF : 22.5000 (unch)
ABBV : 67.73 (-0.40%)
BSTC : 61.03 (-1.85%)
Trade HKMPF with:

Key Turning Points

2nd Resistance Point 22.5000
1st Resistance Point 22.5000
Last Price 22.5000
1st Support Level 22.5000
2nd Support Level 22.5000

See More

52-Week High 26.3964
Last Price 22.5000
Fibonacci 61.8% 21.6610
Fibonacci 50% 20.1982
Fibonacci 38.2% 18.7354
52-Week Low 14.0000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar